Description of Research Expertise

Marcia S. Brose MD PhD Marcia S. Brose, MD, PhD, an international expert in advanced thyroid cancer treatment, has joined the Sidney Kimmel Comprehensive Cancer Center – Jefferson Health as Chief of Cancer Services at Jefferson Torresdale Hospital. Regional Director of Cancer Services for the North Region. Dr. Brose, is a Professor of Medical Oncology and also serves as Medical Director, Community Clinical Research for the SKCCC and Vice Chair of Medical Oncology for TJUH. Prior to August 2021, she served as the director for The Center for Rare Cancers and Personalized Therapy, and the Director of the Center Thyroid Cancer Therapeutics at the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania
Dr. Brose is internationally recognized as a leader in thyroid cancer and personalized cancer care and has been the PI, first author or co-author on many of the pivotal studies to define this new field. She was co-principal investigator (PI) of DECISION, the international Phase III trial of sorafenib for patients with iodine-refractory differentiated thyroid cancer (DTC). Her work was recognized with a plenary lecture to the American Society of Clinical Oncology in 2013, published in The Lancet, and led to the first FDA approval in this indication. She has been a lead on several additional practice-changing clinical trials. Dr. Brose was the PI of the international multicenter phase II study of vemurafenib in patients with RAI-refractory papillary thyroid cancer that harbors the BRAFV600E mutations, the first non-VEGF receptor TKI, and BRAF inhibitor to show activity and was published in Lancet Oncology.
She was co-investigator and co-author of the phase III trials EXAM (cabozantinib in medullary thyroid cancer) and SELECT (lenvatinib in DTC) which were published in the Journal of Clinical Oncology and New England Journal of Medicine. Both led to FDA approvals. Her background in genetics and her interested in personalized therapy also allowed her to participate in the steering committees, and co-author the development and approval three of the new selective inhibitors that have been approved by the FDA for thyroid as well as other cancers that harbor the target mutations: Larotrectinib (published NEJM 2018), selpercatinib (published NEJM 2020), and pralsetinib (publication pending). Most recently her work in the phase I and Phase II setting on cabozantinib resulted in her being chosen as the global PI of COSMIC-311 which showed that cabozantinib is active in patients with RAI-refractory DTC and was presented as an oral abstract at the American Association of Clinical Oncology Annual Meeting 2021, Published in JCO in 2021, and lead to another FDA approval in September of 2021 for Dr. Brose and her Advanced Thyroid Cancer Patients.
Dr. Brose has been invited and continues toto lecture and teach physicians in the US, Europe, Asia, Central and South America on the emerging treatments for personalized therapies and advanced thyroid cancers. She sees patients from across the U.S. and Canada and abroad and regularly is invited to grand rounds to educate surgeons, pathologists, endocrinologists and oncologists on how to incorporate the new systemic treatments using personalized genetic diagnostic information.for advanced thyroid cancer and now for all cancers due to their tumor agnostic applications.
Dr. Brose earned her medical degree from Cornell University Medical College and her doctorate in Genetics and Developmental Biology at The Rockefeller University. She completed her residency in Internal medicine, Fellowship in Hematology/Oncology and post-doctoral work in Cancer Genetics at University of Pennsylvania.

Description of Clinical Expertise

Treatment of Thyroid Cancer, PhaseI/II/III clinical trials, novel drug target discovery, and use of genetic testing in diagnosis, prognostication and prediction of resopnse to the treatment of cancer. Treatment of Rare Cancers of the Head and Neck.

Description of Other Expertise

Dr. Brose regularly instructs and mentors medical students,Internal Medicine and Head and Neck Surgerical residents, fellows (Hematology/Oncology, and Head and Neck Surgery) and post-doctoral PhD fellows who rotate through her lab in Hematology/Oncology and Cell genetics